Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

PALISADE BIO, INC.
Next earnings Aug 10, 2026 · consensus $-0.05 EPS
Last earnings -1.0% on 2026-05-12
Conservative balance sheet (liabilities/equity 0.04x).
PALISADE BIO, INC. shows $0.00 in FY2025 revenue, and -13.0% ROE.
Sources: SEC EDGAR (CIK 0001357459, latest 10-Q filed 2026-05-12) · EODHD · as of 6/22/2026, 7:14:35 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $300K | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$41.9M | -$15.7M | -$13.1M | -$14.9M | -$18.1M |
| Net income | -$26.6M | -$14.3M | -$12.3M | -$14.4M | -$16.8M |
| Diluted EPS | -$169.74 | -$16.53 | -$27.01 | -$10.19 | -$0.30 |
| Net margin | — | — | -4100.0% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
| 2026-06-10 | Baltera Robert Jr. Director | Award | 337K | |
| 2026-06-10 | Wei Binxian Director | Award | 592K | |
| 2026-06-10 | Wei Binxian Director | Exercise | 20.2K | |
| 2026-06-10 | Williams Donald Allen Director | Award | 1.50M | |
| 2026-06-10 | Williams Donald Allen Director | Exercise | 60.7K | |
| 2026-06-10 | Chuang Emil Director | Award | 592K | |
| 2026-06-10 | Chuang Emil Director | Exercise | 20.2K | |
| 2026-06-10 | Zwick Jordan Michael Director | Award | 337K | |
| 2026-02-12 | Jones Mitchell Lawrence Chief Medical Officer | Sell | 1.99K @ $1.75 | $3.48K |
| 2026-02-12 | Finley John David CEO, CFO | Sell | 3.90K @ $1.75 | $6.82K |
| 2026-02-11 | Jones Mitchell Lawrence Chief Medical Officer | Exercise | 8.00K | |
| 2026-02-11 | Finley John David CEO, CFO | Exercise | 13.3K |